The crystal structure of SARS-CoV-2 NSP15 endoribonuclease (PDB ID: 6WXC) in complex with the ligand tipiracil (5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil) was downloaded from the RCSB protein data bank. Using Molecular Operating Environment (MOE; CCG, Montreal, Canada), we analyzed the key binding site residues that are responsible for interaction between the NSP15 and tipiracil and employed a structure-based approach to construct our pharmacophore model of NSP15. The default forcefield is Amber 10: EHT with R Field solvation. Our pharmacophore model was created with seven features and excluded volume R= 1.6 Å. It had 1 donor, 3 acceptors, 1 cationic atom&donor, and 2 hydrophobic centroids. Based on this developed pharmacophore, we conducted a pharmacophore search on our conformational database of 2356 FDA approved drugs. Pharmacophore partial match was used for a 5 of 7 features search.